Epstein-Barr_JJ
virus_NN
nuclear_JJ
protein_NN
2_CD
transactivation_NN
of_IN
the_DT
latent_JJ
membrane_NN
protein_NN
1_CD
promoter_NN
is_VBZ
mediated_VBN
by_IN
J_NN
kappa_NN
and_CC
PU_NN
.1_CD
._.

Expression_NN
of_IN
the_DT
Epstein-Barr_JJ
virus_NN
-LRB-_-LRB-
EBV_NN
-RRB-_-RRB-
latent_JJ
membrane_NN
protein_NN
1_CD
-LRB-_-LRB-
LMP-1_NN
-RRB-_-RRB-
oncogene_NN
is_VBZ
regulated_VBN
by_IN
the_DT
EBV_NN
nuclear_JJ
protein_NN
2_CD
-LRB-_-LRB-
EBNA-2_NN
-RRB-_-RRB-
transactivator_NN
._.

EBNA-2_NN
is_VBZ
known_VBN
to_TO
interact_VB
with_IN
the_DT
cellular_JJ
DNA-binding_JJ
protein_NN
J_NN
kappa_NN
and_CC
is_VBZ
recruited_VBN
to_TO
promoters_NNS
containing_VBG
the_DT
GTGGGAA_NN
J_NN
kappa_NN
recognition_NN
sequence_NN
._.

The_DT
minimal_JJ
EBNA-2-responsive_JJ
LMP-1_NN
promoter_NN
includes_VBZ
one_CD
J_NN
kappa-binding_JJ
site_NN
,_,
and_CC
we_PRP
now_RB
show_VBP
that_IN
mutation_NN
of_IN
that_DT
site_NN
,_,
such_JJ
that_IN
J_NN
kappa_NN
can_MD
not_RB
bind_VB
,_,
reduces_VBZ
EBNA-2_NN
responsiveness_NN
by_IN
60_CD
%_NN
._.

To_TO
identify_VB
other_JJ
factors_NNS
which_WDT
interact_VBP
with_IN
the_DT
LMP-1_NN
EBNA-2_NN
response_NN
element_NN
-LRB-_-LRB-
E2RE_NN
-RRB-_-RRB-
,_,
a_DT
-236_CD
\/_:
-145_CD
minimal_JJ
E2RE_NN
was_VBD
used_VBN
as_IN
a_DT
probe_NN
in_IN
an_DT
electrophoretic_JJ
mobility_NN
shift_NN
assay_NN
._.

The_DT
previously_RB
characterized_VBN
factors_NNS
J_NN
kappa_NN
,_,
PU_NN
.1_CD
,_,
and_CC
AML1_NN
bind_VBP
to_TO
the_DT
LMP-1_NN
E2RE_NN
,_,
along_IN
with_IN
six_CD
other_JJ
unidentified_JJ
factors_NNS
-LRB-_-LRB-
LBF2_NN
to_TO
LBF7_NN
-RRB-_-RRB-
._.

Binding_NN
sites_NNS
were_VBD
mapped_VBN
for_IN
each_DT
factor_NN
._.

LBF4_NN
is_VBZ
B_NN
-_:
and_CC
T-cell_NN
specific_JJ
and_CC
recognizes_VBZ
the_DT
PU_NN
.1_CD
GGAA_NN
core_NN
sequence_NN
as_IN
shown_VBN
by_IN
methylation_NN
interference_NN
._.

LBF4_NN
has_VBZ
a_DT
molecular_JJ
mass_NN
of_IN
105_CD
kDa_NN
and_CC
is_VBZ
probably_RB
unrelated_JJ
to_TO
PU_NN
.1_CD
._.

LBF2_NN
was_VBD
found_VBN
only_RB
in_IN
epithelial_JJ
cell_NN
lines_NNS
,_,
whereas_IN
LBF3_NN
,_,
LBF5_NN
,_,
LBF6_NN
,_,
and_CC
LBF7_NN
were_VBD
not_RB
cell_NN
type_NN
specific_JJ
._.

Mutations_NNS
of_IN
the_DT
AML1_NN
-_:
or_CC
LBF4-binding_JJ
sites_NNS
had_VBD
no_DT
effect_NN
on_IN
EBNA-2_NN
transactivation_NN
,_,
whereas_IN
mutation_NN
of_IN
the_DT
PU.1-binding_JJ
site_NN
completely_RB
eliminated_VBD
EBNA-2_NN
responses_NNS
._.

A_DT
gst-EBNA-2_NN
fusion_NN
protein_NN
specifically_RB
depleted_VBD
PU_NN
.1_CD
from_IN
nuclear_JJ
extracts_NNS
and_CC
bound_VBD
in_FW
vitro_FW
translated_VBN
PU_NN
.1_NN
,_,
providing_VBG
biochemical_JJ
evidence_NN
for_IN
a_DT
direct_JJ
EBNA-2-PU_NN
.1_CD
interaction_NN
._.

Thus_RB
,_,
EBNA-2_NN
transactivation_NN
of_IN
the_DT
LMP-1_NN
promoter_NN
is_VBZ
dependent_JJ
on_IN
interaction_NN
with_IN
at_IN
least_JJS
two_CD
distinct_JJ
sequence-specific_JJ
DNA-binding_JJ
proteins_NNS
,_,
J_NN
kappa_NN
and_CC
PU_NN
.1_CD
._.

LBF3_NN
,_,
LBF5_NN
,_,
LBF6_NN
,_,
or_CC
LBF7_NN
may_MD
also_RB
be_VB
involved_VBN
,_,
since_IN
their_PRP$
binding_VBG
sites_NNS
also_RB
contribute_VBP
to_TO
EBNA-2_NN
responsiveness_NN
._.

